Related references
Note: Only part of the references are listed.Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents
M. Teresa Cibeira et al.
CYTOKINE (2008)
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
Andrea Pellagatti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment
Constantine S. Mitsiades et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
Asher Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson et al.
BLOOD (2006)
Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma
JM Reuben et al.
CANCER (2006)
Immunomodulatory drugs in multiple myeloma
M Zangari et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers
JB Bartlett et al.
BRITISH JOURNAL OF CANCER (2004)
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
K Dredge et al.
BRITISH JOURNAL OF CANCER (2002)
Results of first salvage therapy for patients refractory to a fluidarabine regimen in chronic lymphocytic leukemia
MJ Keating et al.
LEUKEMIA & LYMPHOMA (2002)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating et al.
BLOOD (2002)
3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography
S Stoilova-McPhie et al.
BLOOD (2002)
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion
K Neben et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia
AR Kini et al.
LEUKEMIA (2000)
Share Paper
